Megestrol acetate for weight loss in advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a drug called megestrol acetate to help people with advanced lung cancer who are losing weight or have poor appetite. It aims to improve nutrition and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of advanced (stage III or IV) non-small cell or small cell lung cancer that cannot be removed with surgery.
- You cannot have received chemotherapy for advanced cancer before, but if you had earlier treatment and your cancer returned more than 6 months after it ended, you may still qualify.
- You must have had unintentional weight loss or be at risk for it, along with a decreased appetite or signs of inflammation in your body.
- You need to be between 18 and 75 years old and able to care for yourself (ECOG score 0-2).
- You must have adequate organ function, including acceptable blood counts, liver, kidney, and heart function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a special form of megestrol acetate (a medicine used to help with weight and appetite) can improve outcomes when given alongside standard chemotherapy and radiation for people with stage III non-small cell lung cancer. It is for patients who are not overweight and who are not already using other appetite-boosting medications.
This trial tests a drug called megestrol acetate, which is a type of progesterone that can help increase appetite and reduce weight loss. It is for people with a certain type of lung cancer (small cell lung cancer) that has spread, especially if they are experiencing early signs of weight loss or frailty.
This study tests a medicine called nanocrystalline megestrol acetate to see if it can help improve appetite and promote weight gain in people with advanced non-small cell lung cancer who are losing weight. If you qualify, you would receive this treatment alongside your regular care to help you feel better and maintain your strength.
This study is testing whether a medication called megestrol acetate (a type of hormone that can boost appetite and help with weight gain) can improve outcomes for people with advanced non-small cell lung cancer who are malnourished. It is used as part of first-line treatment, meaning before any chemotherapy for the advanced cancer.
This study tests a special form of megestrol acetate (a medicine that can help with appetite and weight gain) in people with advanced digestive system cancers who are about to start or are already taking a type of targeted therapy called a TKI. The goal is to see if it helps with cancer-related weight loss and wasting (cachexia).
This study tests a special form of the drug megestrol acetate (Megace) in cancer patients who have lost weight and appetite (cachexia). It aims to see if this medication can help improve weight gain and quality of life.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.